Best biotech stocks to buy now: 7 Biotech Stocks to Buy for Breakthrough Treatments and Cures

nasdaq
motley fool

This year, analysts expect revenue to fall another 10% to $9.9 billion. The stock price seems to have already priced in this deceleration as it’s down 55% from its all-time high in June 2021, hit following the FDA approval of Aduhelm. On the other hand, it’s also an opportunity as AMGN’s international sales have been steadily growing, with the company showing particularly strong growth in the Asia-Pacific region. The Dow Jones stock also has a proven record of making successful partnerships and acquisitions to ensure growth and keep its pipeline well-stocked. Twist estimates that its current total addressable market stands at $3 billion per year.

Axsome’s lead drug candidate, which it calls AXS-05, targets depression, Alzheimer’s disease-related agitation, and cigarette smoking cessation. In early 2021, the company filed for U.S. regulatory approval for the drug to treat depression. The company aims to improve human health and wellbeing by harnessing the power of microbial diversity and promoting a healthy microbiome. Seed Health also conducts research to further understand the role of the microbiome in health and disease.

SHARE THIS POST

The company is developing a new platform for gene editing called “NanoKnife” that is designed to be more precise and efficient than existing gene editing technologies. The goal of Eikon Therapeutics is to develop new treatments for a range of genetic diseases, including those that are currently difficult or impossible to treat with existing therapies. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead , Vertex Pharmaceuticals , and Biogen for solid long-term gains. On the optimistic front, Ultragenyx features a strong cash-to-debt ratio of 23.67 times (above 62.39% of the industry). Also, its three-year revenue growth rate pings at 41.5%, outpacing 80.84% of its peers. Finally, Wall Street analysts peg RARE as a near-unanimous strong buy.

Also, their average price target stands at $90, implying 141% upside potential. So far this year, investors appear intrigued at CRSP, sending the stock up more than 8%. However, it struggled in the past 365 days, losing over 29% of its equity value. Financially, the underlying company faces severe profitability hurdles, with its operating and net margins falling well below zero. Therefore, it’s an aspirational entity among biotech stocks to buy. However, it does feature decent stability in the balance sheet, with an equity-to-asset ratio of 0.84 (above the sector median of 0.71).

funds

And this report focuses on the 7 best of these best biotech stocks to buy now primed to soar in the weeks ahead. On January 4, BIIB and Alcyone Therapeutics announced their license and collaboration agreement to evaluate a novel device to improve patient experience and access to neurological ASO therapies. The FDA filing acceptance and granting priority review are important milestones in the mission BIIB and SAGE share to advance the understanding and treatment of depression. SAGE) announced that the FDA had accepted the filing of a New Drug Application for zuranolone in the treatment of the major depressive disorder and postpartum depression .

Free Online Investing Workshop

A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. However, investors must be sure they can handle potential volatility. Since the January opener, EDIT lost nearly 12% of its equity value. If that wasn’t bad enough, Gurufocus warns its readers that Editas may be a possible value trap. Researchers of every level know Bio-Rad for its molecular diagnostic products, both durables, and consumables.

ILMN ranks 9th in our list of the top large-cap biotech stocks to buy now. Illumina develops integrated systems for the analysis of genetic variation and biological function. During the third quarter of 2020, the company reported a revenue of $794 million, an increase of 26% compared to the second quarter of 2020.

drug candidates

Another potential blockbuster is Exicorilant which is in Phase 1 and 2 trials as a treatment for castration-resistant prostate cancers. CORT received approval for Korlym in 2012, and it has steadily grown since then as an approved treatment for adult patients with endogenous Cushing’s syndrome, suffering from type 2 diabetes. The company is working on approval for additional indications that could potentially increase the total addressable market for Korlym. For Cushing’s, the drug has been given orphan status that gives it exclusivity until 2037, although it is being challenged by generic drug manufacturers. The company’s three top-selling drugs are Enbrel for inflammatory diseases, Prolia for osteoporosis and Otezla for plaque psoriasis. These three drugs made up more than 38% of AMGN’s sales last year.

Seagen founder Clay Siegall is back in biotech as CEO of Purdue University spinout

In 2021, 96 biotech companies entered the public market, compared to just eight in 2011. Many of these companies had just a few patents and little to no revenue. Twist Bioscience developed a proprietary technology for “writing” DNA on a silicon chip. The synthetic DNA the company manufactures is used in synthetic genes, next-generation sequencing preparation, and antibody libraries used by biopharma companies to discover and develop drugs. Embark Veterinary is a biotech company that specializes in dog DNA testing. The company offers a comprehensive genetic screening test that can identify over 350 breeds and 190 genetic health risks, helping dog owners better understand their pet’s health and behavior.

Incyte Corporation is a global pharmaceutical company that focuses on finding solutions for unmet medical needs. Their research is focused on transforming the treatment of cancer and inflammatory and autoimmune conditions. During the third quarter of 2020, the company reported a total product and royalty revenue of $621 million. But what many investors overlook is that Merck is much more than the $4.8 billion in revenue that Keytruda produced in the first quarter of 2022. The company’s COVID-19 antiviral treatment Lagevrio recorded $3.2 billion in revenue during the quarter. And Merck’s human papilloma virus vaccine Gardasil logged $1.5 billion in revenue in the first quarter, which was a double-digit growth rate over the prior year.

Provention Bio, Inc. (NASDAQ:PRVB)

AMGN has shown steady growth in recent years and its 2021 results were no different. For the full year, AMGN recorded earnings of $17.10 per share and revenue of $26 billion, up 6% and 2.1% year-over-year, respectively. This year, analysts are forecasting a modest improvement to $17.65 in earnings per share and $26.2 billion in revenue.

Maze Therapeutics’ focus is on creating novel medicines through insights gained from further understanding of human genetics. Their goal is to help those suffering from rare ailments by understanding the genetic markers that occur in people who don’t suffer from these diseases. Financial backers of Maze Therapeutics include GV, ARCH Venture Partners, Casdin Capital, and others. Inflammatix is a biotech startup that develops diagnostic tests to quickly identify and categorize acute infections, including sepsis and COVID-19. Using machine learning and genomic analysis, their tests measure the immune system’s response to the infection and provide rapid results to help doctors make informed treatment decisions.

The 3 Best Growth Stocks to Buy in the Biotech Sector – InvestorPlace

The 3 Best Growth Stocks to Buy in the Biotech Sector.

Posted: Thu, 30 Mar 2023 02:24:10 GMT [source]

These drugs are developed by companies after years of costly research and trials, a somewhat unpredictable process. As reported by Bloomberg, several ground-breaking discoveries are in the process and are likely to boost market potential in the specified disease categories. The number of new medicine approvals is expected to increase due to favorable regulatory conditions and an increase in clinical trial submissions to the FDA.

Acer Therapeutics Inc. (NASDAQ:ACER)

These firms ensure that there is years of research and extended trials before a product is approved for commercial production. As such, for investors looking to turn quick profits, opportunities are few and far between, since it is not altogether easy to predict success. The success and failure stories of coronavirus vaccine developers are a classic example.

  • As a whole, the biotechnology sector relies heavily on technology for progress.
  • These include cancer, cardiovascular issues, eye disease, inflammation and asthma.
  • The bottom line is that Bio-Rad is a company used by almost every American lab with NIH funding.
  • These include Tecfidera, Vumerity, Spinraza and Fumaderm to name a few.

Some on https://forex-world.net/ are concerned with the company’s pipeline beyond CF. That’s especially true after it stopped its trial to treat a rare genetic disorder affecting the liver and lungs, even after positive phase 2 data. Management felt that the results wouldn’t translate to meaningful clinical benefit. In this article, we discuss the 12 best biotech stocks to buy under $10. If you want to see more stocks in this selection, check out 5 Best Biotech Stocks To Buy Under $10.

The report suggested that the new facility would have the capability to manufacture vaccines at scale. That it was the first European firm to conduct COVID-19 vaccine trials on humans. The company partnered with pharma giant Pfizer for the testing which was ultimately successful. Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999. Finally, Axsome has two other drugs — AXS-07 for treating migraines and AXS-14 for fibromyalgia — that it plans to submit for FDA approval this year. Since the January opener, ROIV only managed to pop up less than half a percent.

Why Bluebird Bio Stock Is Sinking This Week – Nasdaq

Why Bluebird Bio Stock Is Sinking This Week.

Posted: Thu, 30 Mar 2023 17:54:00 GMT [source]

Get Started Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content. The biotech stock broke out of a consolidation with a buy point at 21.15 in early February and has since bounded into and out of a buy zone. Its latest-stage testing is in chronic myeloid leukemia, lung cancer and other solid tumors. Beyond that, Vertex is testing treatments for liver and kidney diseases, Duchenne muscular dystrophy and pain. This combination of stellar earnings growth and low price provides a great catalyst for investor success.